Society For Immunotherapy Of Cancer Inc
- Assets
- $21.9m
- Revenue
- $14.2m
- Investments
- $0.0
- Employees
- 0
- Location
- Milwaukee, WI
- Founding
- 08/1993
- Data as of
- 12/2021
- EIN
- 39-1554806
Organization Overview
Society For Immunotherapy Of Cancer Inc is located in Milwaukee, WI. The organization was established in 1993. According to its NTEE Classification (E50) the organization is classified as: Rehabilitative Care, under the broad grouping of Health Care and related organizations. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Society For Immunotherapy Of Cancer Inc is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2021, Society For Immunotherapy Of Cancer Inc generated $14.2m in total revenue. This represents relatively stable growth, over the past 7 years the organization has increased revenue by an average of 7.9% each year. All expenses for the organization totaled $11.3m during the year ending 12/2021. While expenses have increased by 11.4% per year over the past 7 years. They've been increasing with an increasing level of total revenue. You can explore the organizations financials more deeply in the financial statements section below.
Since 2015, Society For Immunotherapy Of Cancer Inc has awarded 58 individual grants totaling $4,442,078. If you would like to learn more about the grant giving history of this organization, scroll down to the grant profile section of this page.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2021
Describe the Organization's Mission:
Part 3 - Line 1
TO IMPROVE CANCER PATIENT OUTCOMES BY ADVANCING THE SCIENCE, DEVELOPMENT AND APPLICATION OF CANCER IMMUNOLOGY AND IMMUNOTHERAPY THROUGH OUR CORE VALUES OF INTERACTION/INTEGRATION, INNOVATION, TRANSLATION AND LEADERSHIP IN THE FIELD. SITC AIMS TO MAKE CANCER IMMUNOTHERAPY A STANDARD OF CARE AND THE WORD "CURE" A REALITY FOR CANCER PATIENTS EVERYWHERE.
Describe the Organization's Program Activity:
Part 3 - Line 4a
THE SOCIETY FOR IMMUNOTHERAPY OF CANCER'S (SITC) 37TH ANNUAL MEETING & PRE-CONFERENCE PROGRAMS (SITC 2022) PROVIDED A MULTIDISCIPLINARY EDUCATIONAL AND INTERACTIVE ENVIRONMENT FOCUSED ON IMPROVING THE OUTCOME FOR CURRENT AND FUTURE PATIENTS WITH CANCER BY INCORPORATING STRATEGIES BASED ON BASIC AND APPLIED CANCER IMMUNOTHERAPY. THE ANNUAL MEETING CONSISTED OF CUTTING-EDGE RESEARCH PRESENTATIONS BY EXPERTS IN THE FIELD, ORAL AND POSTER ABSTRACT PRESENTATIONS AND AMPLE OPPORTUNITY FOR STRUCTURED AND INFORMAL DISCUSSIONS, INCLUDING IMPORTANT NETWORKING OPPORTUNITIES. IN ADDITION, THE MEETING INCLUDES UPDATES ON MAJOR NATIONAL AND INTERNATIONAL INITIATIVES COMING FROM ACADEMIA, GOVERNMENT AND INDUSTRY, AS WELL AS IMPORTANT SOCIETY PROJECTS.
WORKSHOP / CONNECTED / PRIMER / WIC/ INDUSTRY / WINTER / WIN / INTERIM PROGRAM / SPARKATHON PROGRAM / JOURNAL / COLLABORATIVE EDUCATION PROGRAMS / CIG / POLICY ACTIVITIES / SCIENTIFIC RESOURCES / OTHER PROGRAM SERVICES
SITC'S FORWARD FUND IS AN INITIATIVE ESTABLISHED BY SITC IN 2012 TO STIMULATE THE FUTURE OF THE SCIENCE, DEVELOPMENT AND APPLICATION OF CANCER IMMUNOLOGY AND IMMUNOTHERAPY THROUGH FINANCIALLY SUPPORTING ITS EDUCATION AND RESEARCH. SINCE INCEPTION, THE FORWARD FUND HAS AWARDED MORE THAN $5 MILLION TOWARD PROGRAMS, GRANTS AND INITIATIVES THAT SUPPORT EARLY CAREER SCIENTISTS THROUGH RESEARCH AND EDUCATION. FROM THE GENEROSITY OF OUR DONORS, HUNDREDS OF EARLY CAREER SCIENTISTS' CAREERS HAVE BEEN SHAPED BY THE FORWARD FUND. BY PROVIDING FELLOWSHIPS, YOUNG INVESTIGATOR AWARDS AND THE ONE-OF-A-KIND SITC SPARKATHON, SITC IS INSPIRING THE NEXT GENERATION, ADVANCING THE SCIENCE AND TACKLING THE HURDLES FACING THE FIELD.
THE ADVANCES IN CANCER IMMUNOTHERAPY (ACI) REGIONAL SERIES HOSTED FIFTEEN REGIONAL CME-, CNE- AND CPE-CERTIFIED PROGRAMS IN 2022. THE SERIES WAS DESIGNED TO PROVIDE EDUCATION TO PATIENT CARE PROVIDERS AND OTHERS WHO WISH TO LEARN THE BASIC PRINCIPLES OF TUMOR IMMUNOLOGY AND IMMUNOTHERAPY, AND TO IMPROVE THEIR ABILITY TO INTEGRATE IMMUNOTHERAPY INTO STATE-OF-THE-ART CLINICAL MANAGEMENT FOR THEIR PATIENTS. THIS INTENDED AUDIENCE INCLUDED CLINICAL ONCOLOGISTS, REGISTERED NURSES, NURSE PRACTITIONERS, PHARMACISTS, EMERGENCY PHYSICIANS, ALLIED HEALTH PROFESSIONALS, OTHER PATIENT CARE PROVIDERS, STUDENTS AND PATIENT ADVOCATES.
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
Patrick Hwu MD President | OfficerTrustee | 5 | $0 |
Leisha Emens MD PHD Vice President | OfficerTrustee | 5 | $5,000 |
Jedd Wolchok MD PHD Secr/treasurer | OfficerTrustee | 5 | $0 |
Mario Sznol MD Imm. Past Pres. | OfficerTrustee | 5 | $0 |
Alessandra Cesano MD PHD Director | Trustee | 1 | $0 |
Tanja DE Gruijl PHD Director | Trustee | 1 | $0 |
Outside Vendors & Contractors
| Vendor Name (Service) | Service Year | Compensation |
|---|---|---|
Executive Director Inc Management | 12/30/22 | $5,983,764 |
Cornerstone Government Affairs Inc Consulting | 12/30/22 | $180,000 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Federated campaigns | $0 |
| Membership dues | $0 |
| Fundraising events | $0 |
| Related organizations | $0 |
| Government grants | $0 |
| All other contributions, gifts, grants, and similar amounts not included above | $3,646,330 |
| Noncash contributions included in lines 1a–1f | $0 |
| Total Revenue from Contributions, Gifts, Grants & Similar | $3,646,330 |
| Total Program Service Revenue | $10,142,186 |
| Investment income | $172,749 |
| Tax Exempt Bond Proceeds | $0 |
| Royalties | $5,568 |
| Net Rental Income | $0 |
| Net Gain/Loss on Asset Sales | $0 |
| Net Income from Fundraising Events | $48,837 |
| Net Income from Gaming Activities | $0 |
| Net Income from Sales of Inventory | $332 |
| Miscellaneous Revenue | $0 |
| Total Revenue | $14,185,558 |
| Statement of Expenses | |
|---|---|
| Grants and other assistance to domestic organizations and domestic governments. | $616,489 |
| Grants and other assistance to domestic individuals. | $7,155 |
| Grants and other assistance to Foreign Orgs/Individuals | $0 |
| Benefits paid to or for members | $0 |
| Compensation of current officers, directors, key employees. | $9,000 |
| Compensation of current officers, directors, key employees. | $0 |
| Compensation to disqualified persons | $0 |
| Other salaries and wages | $0 |
| Pension plan accruals and contributions | $0 |
| Other employee benefits | $0 |
| Payroll taxes | $0 |
| Fees for services: Management | $5,555,690 |
| Fees for services: Legal | $2,987 |
| Fees for services: Accounting | $14,000 |
| Fees for services: Lobbying | $0 |
| Fees for services: Fundraising | $0 |
| Fees for services: Investment Management | $21,479 |
| Fees for services: Other | $464 |
| Advertising and promotion | $53,417 |
| Office expenses | $39,241 |
| Information technology | $56,400 |
| Royalties | $0 |
| Occupancy | $0 |
| Travel | $0 |
| Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
| Conferences, conventions, and meetings | $4,712,616 |
| Interest | $0 |
| Payments to affiliates | $0 |
| Depreciation, depletion, and amortization | $0 |
| Insurance | $5,329 |
| All other expenses | $25,620 |
| Total functional expenses | $11,322,716 |
| Balance Sheet | |
|---|---|
| Cash—non-interest-bearing | $5,838,342 |
| Savings and temporary cash investments | $6,492,322 |
| Pledges and grants receivable | $136,521 |
| Accounts receivable, net | $472,565 |
| Loans from Officers, Directors, or Controlling Persons | $0 |
| Loans from Disqualified Persons | $0 |
| Notes and loans receivable | $0 |
| Inventories for sale or use | $1,091 |
| Prepaid expenses and deferred charges | $149,035 |
| Net Land, buildings, and equipment | $0 |
| Investments—publicly traded securities | $8,823,503 |
| Investments—other securities | $0 |
| Investments—program-related | $0 |
| Intangible assets | $0 |
| Other assets | $13,306 |
| Total assets | $21,926,685 |
| Accounts payable and accrued expenses | $1,115,768 |
| Grants payable | $0 |
| Deferred revenue | $2,027,478 |
| Tax-exempt bond liabilities | $0 |
| Escrow or custodial account liability | $0 |
| Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
| Secured mortgages and notes payable | $0 |
| Unsecured mortgages and notes payable | $0 |
| Other liabilities | $0 |
| Total liabilities | $3,143,246 |
| Net assets without donor restrictions | $16,636,189 |
| Net assets with donor restrictions | $2,147,250 |
| Capital stock or trust principal, or current funds | $0 |
| Paid-in or capital surplus, or land, building, or equipment fund | $0 |
| Retained earnings, endowment, accumulated income, or other funds | $0 |
| Total liabilities and net assets/fund balances | $21,926,685 |
Grants Awarded
Over the last fiscal year, Society For Immunotherapy Of Cancer Inc has awarded $685,589 in support to 12 organizations.
| Grant Recipient | Amount |
|---|---|
DANA-FARBER CANCER INSTITUTE PURPOSE: FELLOWSHIP AWARD | $50,000 |
MASSACHUSETTS INSTITUTE OF TECHNOLOGY PURPOSE: FELLOWSHIP AWARD | $25,000 |
REGENTS OF THE UNIVERSITY OF CALIFORNIA PURPOSE: FELLOWSHIP AWARD | $50,000 |
MEMORIAL SLOAN-KETTERING CANCER CENTER PURPOSE: FELLOWSHIP AWARD | $100,000 |
THE CHILDREN'S HOSPITAL OF PHILADELPHIA PURPOSE: FELLOWSHIP AWARD | $75,000 |
UNIVERSITY OF FLORIDA PURPOSE: FELLOWSHIP AWARD | $50,000 |